[
  {
    "drugid": "RxNorm:190521",
    "drugname": "abacavir",
    "guidelinename": "HLA-B and Abacavir",
    "url": "https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166104997"
    ],
    "genes": [
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110014,
        "guidelineid": 100421,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing",
        "authors": [
          "Martin M A",
          "Klein T E",
          "Dong B J",
          "Pirmohamed M",
          "Haas D W",
          "Kroetz D L"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 2,
        "page": "",
        "volume": "",
        "year": 2012,
        "pmid": "22378157",
        "pmcid": "PMC3374459",
        "doi": "10.1038/clpt.2011.355",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157.pdf"
      },
      {
        "id": 110015,
        "guidelineid": 100421,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update",
        "authors": [
          "Martin Michael A",
          "Hoffman James M",
          "Freimuth Robert R",
          "Klein Teri E",
          "Dong Betty J",
          "Pirmohamed Munir",
          "Hicks J Kevin",
          "Wilkinson Mark R",
          "Haas David W",
          "Kroetz Deanna L"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 2,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24561393",
        "pmcid": "PMC3994233",
        "doi": "10.1038/clpt.2014.38",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-B": "Low or reduced risk of abacavir hypersensitivity"
        },
        "drugrecommendation": "Use abacavir per standard dosing guidelines",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*57:01 negative"
        },
        "lookupkey": {
          "HLA-B": "*57:01 negative"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "HLA-B": "Significantly increased risk of abacavir hypersensitivity"
        },
        "drugrecommendation": "Abacavir is not recommended",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*57:01 positive"
        },
        "lookupkey": {
          "HLA-B": "*57:01 positive"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:519",
    "drugname": "allopurinol",
    "guidelinename": "HLA-B and Allopurinol",
    "url": "https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166105003"
    ],
    "genes": [
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110018,
        "guidelineid": 100422,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update",
        "authors": [
          "Saito Y",
          "Stamp L K",
          "Caudle K E",
          "Hershfield M S",
          "McDonagh E M",
          "Callaghan J T",
          "Tassaneeyakul W",
          "Mushiroda T",
          "Kamatani N",
          "Goldspiel B R",
          "Phillips E J",
          "Klein T E",
          "Lee Mtm"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 6,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "26094938",
        "pmcid": "PMC4675696",
        "doi": "10.1002/cpt.161",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938.pdf"
      },
      {
        "id": 110027,
        "guidelineid": 100422,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing",
        "authors": [
          "Hershfield M S",
          "Callaghan J T",
          "Tassaneeyakul W",
          "Mushiroda T",
          "Thorn C F",
          "Klein T E",
          "Lee M T M"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 10,
        "page": "",
        "volume": "",
        "year": 2012,
        "pmid": "23232549",
        "pmcid": "PMC3564416",
        "doi": "10.1038/clpt.2012.209",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-B": "Low or reduced risk of allopurinol-induced SCAR"
        },
        "drugrecommendation": "Use allopurinol per standard dosing guidelines",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*58:01 negative"
        },
        "lookupkey": {
          "HLA-B": "*58:01 negative"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "HLA-B": "Significantly increased risk of allopurinol-induced SCAR"
        },
        "drugrecommendation": "Allopurinol is contraindicated",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*58:01 positive"
        },
        "lookupkey": {
          "HLA-B": "*58:01 positive"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:704",
    "drugname": "amitriptyline",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2C19",
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:343047",
    "drugname": "atazanavir",
    "guidelinename": "UGT1A1 and Atazanavir",
    "url": "https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/",
    "guidelinepharmgkbids": [
      "PA166128738"
    ],
    "genes": [
      "UGT1A1"
    ],
    "citations": [
      {
        "id": 110008,
        "guidelineid": 100429,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing",
        "authors": [
          "Gammal Roseann S",
          "Court Michael H",
          "Haidar Cyrine E",
          "Iwuchukwu Otito Frances",
          "Gaur Aditya H",
          "Alvarellos Maria",
          "Guillemette Chantal",
          "Lennox Jeffrey L",
          "Whirl-Carrillo Michelle",
          "Brummel Sean",
          "Ratain Mark J",
          "Klein Teri E",
          "Schackman Bruce R",
          "Caudle Kelly E",
          "Haas David W"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 9,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "26417955",
        "pmcid": "PMC4785051",
        "doi": "10.1002/cpt.269",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/atazanavir/2015/26417955.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "UGT1A1": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "UGT1A1": "Indeterminate"
        },
        "activityscore": {
          "UGT1A1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "UGT1A1": "Indeterminate"
        },
        "comments": "UGT1A1*80 is in very high linkage disequilibrium with *28 and *37. In the rare event that *80 is detected but *28 and *37 are not, there are not enough clinical data to predict metabolizer status with certainty. However, if only *80 is interrogated and the patient is heterozygous or homozygous for *80, an intermediate or poor metabolizer phenotype may be inferred, respectively.",
        "population": "general"
      },
      {
        "implications": {
          "UGT1A1": "Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir."
        },
        "drugrecommendation": "There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",
        "classification": "Strong",
        "phenotypes": {
          "UGT1A1": "Intermediate Metabolizer"
        },
        "activityscore": {
          "UGT1A1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "UGT1A1": "Intermediate Metabolizer"
        },
        "comments": "All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.",
        "population": "general"
      },
      {
        "implications": {
          "UGT1A1": "Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir."
        },
        "drugrecommendation": "There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",
        "classification": "Strong",
        "phenotypes": {
          "UGT1A1": "Normal Metabolizer"
        },
        "activityscore": {
          "UGT1A1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "UGT1A1": "Normal Metabolizer"
        },
        "comments": "All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat. \"reference\" function refers to the UGT1A1 allele to which other alleles are compared.",
        "population": "general"
      },
      {
        "implications": {
          "UGT1A1": "Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir."
        },
        "drugrecommendation": "Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).",
        "classification": "Strong",
        "phenotypes": {
          "UGT1A1": "Poor Metabolizer"
        },
        "activityscore": {
          "UGT1A1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "UGT1A1": "Poor Metabolizer"
        },
        "comments": "All studies correlating UGT1A1 genotypes with atazanavir adverse events have involved ritonavir boosting. However, concentration-time profiles are equivalent when boosted with either cobicistat or ritonavir (PMID 23532097), and bilirubin-related adverse events including discontinuation of atazanavir occur in a similar percentage of patients prescribed atazanavir with cobicistat or ritonavir (PMID 23532097). Associations between UGT1A1 genotype, bilirubin elevations, and atazanavir/r discontinuation therefore almost certainly translate to atazanavir/cobicistat.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:38400",
    "drugname": "atomoxetine",
    "guidelinename": "CYP2D6 and Atomoxetine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/",
    "guidelinepharmgkbids": [
      "PA166181885"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110035,
        "guidelineid": 104243,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.",
        "authors": [
          "Brown Jacob T",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Nurmi Erika L",
          "Mueller Daniel J",
          "Dinh Jean C",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Caudle Kelly E",
          "McCracken James T",
          "de Leon Jose",
          "Steven Leeder J"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 2,
        "page": "",
        "volume": "",
        "year": 2019,
        "pmid": "30801677",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/atomoxetine/2019/30801677.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Intermediate metabolizers with an activity score of 1 may be at an increased risk of discontinuation as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL. Doses above 120 mg/day have not been evaluated.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing."
        },
        "drugrecommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Therapeutic range of 200 to 1000 ng/mL has been proposed (PMID 29493375). Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response. Available information suggests that clinical response is greater in poor metabolizers (PMs) compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose. Furthermore, modest improvement in response, defined as reduction in ADHD-rating scale, is observed at peak concentrations greater than 400 ng/mL.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "pediatrics"
      }
    ]
  },
  {
    "drugid": "RxNorm:1256",
    "drugname": "azathioprine",
    "guidelinename": "TPMT, NUDT15 and Thiopurines",
    "url": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/",
    "guidelinepharmgkbids": [
      "PA166104933",
      "PA166104945",
      "PA166104965"
    ],
    "genes": [
      "NUDT15",
      "TPMT"
    ],
    "citations": [
      {
        "id": 110017,
        "guidelineid": 100428,
        "title": "Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": "387-91",
        "volume": "89",
        "year": 2011,
        "pmid": "21270794",
        "pmcid": "PMC3098761",
        "doi": "10.1038/clpt.2010.320",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794.pdf"
      },
      {
        "id": 110024,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Hicks J K",
          "Schwab M",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23422873",
        "pmcid": "PMC3604643",
        "doi": "10.1038/clpt.2013.4",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873.pdf"
      },
      {
        "id": 110026,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.",
        "authors": [
          "Relling Mary V",
          "Schwab Matthias",
          "Whirl-Carrillo Michelle",
          "Suarez-Kurtz Guilherme",
          "Pui Ching-Hon",
          "Stein Charles M",
          "Moyer Ann M",
          "Evans William E",
          "Klein Teri E",
          "Antillon-Klussmann Federico Guillermo",
          "Caudle Kelly E",
          "Kato Motohiro",
          "Yeoh Allen E J",
          "Schmiegelow Kjeld",
          "Yang Jun J"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30447069",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:194000",
    "drugname": "capecitabine",
    "guidelinename": "DPYD and Fluoropyrimidines",
    "url": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/",
    "guidelinepharmgkbids": [
      "PA166109594",
      "PA166122686",
      "PA166122687"
    ],
    "genes": [
      "DPYD"
    ],
    "citations": [
      {
        "id": 110019,
        "guidelineid": 100419,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing",
        "authors": [
          "Caudle Kelly E",
          "Thorn Caroline F",
          "Klein Teri E",
          "Swen Jesse J",
          "McLeod Howard L",
          "Diasio Robert B",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23988873",
        "pmcid": "PMC3831181",
        "doi": "10.1038/clpt.2013.172",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2013/23988873.pdf"
      },
      {
        "id": 110029,
        "guidelineid": 100419,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",
        "authors": [
          "Amstutz Ursula",
          "Henricks Linda M",
          "Offer Steven M",
          "Barbarino Julia",
          "Schellens Jan H M",
          "Swen Jesse J",
          "Klein Teri E",
          "McLeod Howard L",
          "Caudle Kelly E",
          "Diasio Robert B",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2017,
        "pmid": "29152729",
        "pmcid": "PMC5760397",
        "doi": "10.1002/cpt.911",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."
        },
        "drugrecommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Poor Metabolizer"
        },
        "activityscore": {
          "DPYD": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."
        },
        "drugrecommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Poor Metabolizer"
        },
        "activityscore": {
          "DPYD": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "0.5"
        },
        "comments": "If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance. Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue therapy if the drug level is too high.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"
        },
        "drugrecommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Intermediate Metabolizer"
        },
        "activityscore": {
          "DPYD": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "1"
        },
        "comments": "Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"
        },
        "drugrecommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
        "classification": "Moderate",
        "phenotypes": {
          "DPYD": "Intermediate Metabolizer"
        },
        "activityscore": {
          "DPYD": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "1.5"
        },
        "comments": "Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity"
        },
        "drugrecommendation": "Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Normal Metabolizer"
        },
        "activityscore": {
          "DPYD": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "2"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:2002",
    "drugname": "carbamazepine",
    "guidelinename": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine",
    "url": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166105008",
      "PA166176623"
    ],
    "genes": [
      "HLA-A",
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110009,
        "guidelineid": 100423,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing",
        "authors": [
          "Leckband Susan G",
          "Kelsoe John R",
          "Dunnenberger H Mark",
          "George Alfred L",
          "Tran Eric",
          "Berger Reisel",
          "Müller Daniel J",
          "Whirl-Carrillo Michelle",
          "Caudle Kelly E",
          "Pirmohamed Munir"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23695185",
        "pmcid": "PMC3748365",
        "doi": "10.1038/clpt.2013.103",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2013/23695185.pdf"
      },
      {
        "id": 110034,
        "guidelineid": 100423,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.",
        "authors": [
          "Phillips Elizabeth J",
          "Sukasem Chonlaphat",
          "Whirl-Carrillo Michelle",
          "Müller Daniel J",
          "Dunnenberger Henry M",
          "Chantratita Wasun",
          "Goldspiel Barry",
          "Chen Yuan-Tsong",
          "Carleton Bruce C",
          "George Alfred L",
          "Mushiroda Taisei",
          "Klein Teri",
          "Gammal Roseann S",
          "Pirmohamed Munir"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 4,
        "page": "574-581",
        "volume": "103",
        "year": 2018,
        "pmid": "29392710",
        "pmcid": "PMC5847474",
        "doi": "10.1002/cpt.1004",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/29392710.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "No *15:02 result"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "No *15:02 result"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Normal risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 negative",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 negative",
          "HLA-B": "No *15:02 result"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 negative"
        },
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 negative"
        },
        "comments": "Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 negative"
        },
        "comments": "n/a",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve and alternative agents are available, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "No *15:02 result"
        },
        "comments": "Other aromatic anticonvulsants have very limited evidence, if any, linking SJS/TEN, DRESS, and/or MPE with the HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "No *15:02 result"
        },
        "comments": "n/a",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "Greater risk of carbamazepine-induced SJS/TEN, DRESS, and MPE",
          "HLA-B": "n/a"
        },
        "drugrecommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "HLA-A*31:01 positive",
          "HLA-B": "No HLA-B*15:02 result"
        },
        "lookupkey": {
          "HLA-A": "*31:01 positive",
          "HLA-B": "No *15:02 result"
        },
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ use >3mos "
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Normal risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use carbamazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 negative"
        },
        "comments": "HLA-B*15:02 has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of HLA-B*15:02 for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative HLA-B*15:02 test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN (PMID 25355835).",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ-no alternatives"
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is carbamazepine-naïve, do not use carbamazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ naive"
      },
      {
        "implications": {
          "HLA-A": "n/a",
          "HLA-B": "Greater risk of carbamazepine-induced SJS/TEN"
        },
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-A": "No HLA-A*31:01 result",
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-A": "No *31:01 result",
          "HLA-B": "*15:02 positive"
        },
        "comments": "Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital. In addition to HLA-B*15:02, risk for carbamazepine-induced SJS/TEN has been reported in association with the most common B75 serotype alleles in Southeast Asia, HLA-B*15:08, HLA-B*15:11, and HLA-B*15:21. Although not described, the possibility of carbamazepine-induced SJS/TEN in association with less frequently carried B75 serotype alleles, such as HLA-B*15:30 and HLA-B*15:31, should also be considered.",
        "population": "CBZ use >3mos "
      }
    ]
  },
  {
    "drugid": "RxNorm:140587",
    "drugname": "celecoxib",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:2556",
    "drugname": "citalopram",
    "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
    "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166127636",
      "PA166127637",
      "PA166127638",
      "PA166127639"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 110006,
        "guidelineid": 100413,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
        "authors": [
          "Hicks J Kevin",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Müller Daniel J",
          "Ji Yuan",
          "Leckband Susan G",
          "Leeder J Steven",
          "Graham Rebecca L",
          "Chiulli Dana L",
          "LLerena Adrián",
          "Skaar Todd C",
          "Scott Stuart A",
          "Stingl Julia C",
          "Klein Teri E",
          "Caudle Kelly E",
          "Gaedigk Andrea"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25974703",
        "pmcid": "PMC4512908",
        "doi": "10.1002/cpt.147",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:2597",
    "drugname": "clomipramine",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2C19",
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:32968",
    "drugname": "clopidogrel",
    "guidelinename": "CYP2C19 and Clopidogrel",
    "url": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104948"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 110005,
        "guidelineid": 100411,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy",
        "authors": [
          "Scott S A",
          "Sangkuhl K",
          "Gardner E E",
          "Stein C M",
          "Hulot J-S",
          "Johnson J A",
          "Roden D M",
          "Klein T E",
          "Shuldiner A R"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 6,
        "page": "",
        "volume": "",
        "year": 2011,
        "pmid": "21716271",
        "pmcid": "PMC3234301",
        "doi": "10.1038/clpt.2011.132",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2011/21716271.pdf"
      },
      {
        "id": 110028,
        "guidelineid": 100411,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update",
        "authors": [
          "Scott Stuart A",
          "Sangkuhl Katrin",
          "Stein C Michael",
          "Hulot Jean-Sébastien",
          "Mega Jessica L",
          "Roden Dan M",
          "Klein Teri E",
          "Sabatine Marc S",
          "Johnson Julie A",
          "Shuldiner Alan R"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23698643",
        "pmcid": "PMC3748366",
        "doi": "10.1038/clpt.2013.105",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2013/23698643.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal platelet inhibition; normal residual platelet aggregation"
        },
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events"
        },
        "drugrecommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased platelet inhibition; decreased residual platelet aggregation"
        },
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "The CYP2C19*17 allele may be associated with increased bleeding risks.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased platelet inhibition; decreased residual platelet aggregation"
        },
        "drugrecommendation": "Clopidogrel: label-recommended dosage and administration",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "The CYP2C19*17 allele may be associated with increased bleeding risks.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:2670",
    "drugname": "codeine",
    "guidelinename": "CYP2D6, OPRM1, COMT, and Opioids",
    "url": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
    "guidelinepharmgkbids": [
      "PA166104996"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110031,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype",
        "authors": [
          "Crews K R",
          "Gaedigk A",
          "Dunnenberger H M",
          "Klein T E",
          "Shen D D",
          "Callaghan J T",
          "Kharasch E D",
          "Skaar T C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2011,
        "pmid": "22205192",
        "pmcid": "PMC3289963",
        "doi": "10.1038/clpt.2011.287",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192.pdf"
      },
      {
        "id": 110033,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update",
        "authors": [
          "Crews Kristine R",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steve",
          "Klein Teri E",
          "Caudle Kelly E",
          "Haidar Cyrine E",
          "Shen Danny D",
          "Callaghan John T",
          "Sadhasivam Senthilkumar",
          "Prows Cynthia A",
          "Kharasch Evan D",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24458010",
        "pmcid": "PMC3975212",
        "doi": "10.1038/clpt.2013.254",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010.pdf"
      },
      {
        "id": 417705,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.",
        "authors": [
          "Crews Kristine R",
          "Monte Andrew A",
          "Huddart Rachel",
          "Caudle Kelly E",
          "Kharasch Evan D",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steven",
          "Callaghan John T",
          "Samer Caroline Flora",
          "Klein Teri E",
          "Haidar Cyrine E",
          "Van Driest Sara L",
          "Ruano Gualberto",
          "Sangkuhl Katrin",
          "Cavallari Larisa H",
          "Müller Daniel J",
          "Prows Cynthia A",
          "Nagy Mohamed",
          "Somogyi Andrew A",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": null,
        "volume": null,
        "year": 2021,
        "pmid": "33387367",
        "pmcid": null,
        "doi": "10.1002/cpt.2149",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced morphine formation leading to diminished analgesia."
        },
        "drugrecommendation": "Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected morphine formation"
        },
        "drugrecommendation": "Use codeine label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of morphine leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:27340",
    "drugname": "desflurane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:3247",
    "drugname": "desipramine",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:816346",
    "drugname": "dexlansoprazole",
    "guidelinename": "CYP2C19 and Proton Pump Inhibitors",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166219103",
      "PA166219301"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 571447,
        "guidelineid": 110076,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
        "authors": [
          "Lima John J",
          "Thomas Cameron D",
          "Barbarino Julia",
          "Desta Zeruesenay",
          "Van Driest Sara L",
          "El Rouby Nihal",
          "Johnson Julie A",
          "Cavallari Larisa H",
          "Shakhnovich Valentina",
          "Thacker David L",
          "Scott Stuart A",
          "Schwab Matthias",
          "Uppugunduri Chakradhara Rao S",
          "Formea Christine M",
          "Franciosi James P",
          "Sangkuhl Katrin",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Gammal Roseann S",
          "Furuta Takahisa"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32770672",
        "pmcid": null,
        "doi": "10.1002/cpt.2015",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:3638",
    "drugname": "doxepin",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2C19",
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:195085",
    "drugname": "efavirenz",
    "guidelinename": "CYP2B6 and efavirenz",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/",
    "guidelinepharmgkbids": [
      "PA166182603"
    ],
    "genes": [
      "CYP2B6"
    ],
    "citations": [
      {
        "id": 110036,
        "guidelineid": 104245,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy.",
        "authors": [
          "Desta Zeruesenay",
          "Gammal Roseann S",
          "Gong Li",
          "Whirl-Carrillo Michelle",
          "Gaur Aditya H",
          "Sukasem Chonlaphat",
          "Hockings Jennifer",
          "Myers Alan",
          "Swart Marelize",
          "Tyndale Rachel",
          "Masimirembwa Collen",
          "Iwuchukwu Otito F",
          "Chirwa Sanika",
          "Lennox Jeffrey",
          "Gaedigk Andrea",
          "Klein Teri",
          "Haas David W"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 4,
        "page": "",
        "volume": "",
        "year": 2019,
        "pmid": "31006110",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 2,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/efavirenz/2019/31006110.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2B6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2B6": "Indeterminate"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Indeterminate"
        },
        "comments": "n/a",
        "population": "child >40kg_adult"
      },
      {
        "implications": {
          "CYP2B6": "Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events"
        },
        "drugrecommendation": "Consider initiating efavirenz with decreased dose of 400 mg/day",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2B6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Intermediate Metabolizer"
        },
        "comments": "If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.",
        "population": "child >40kg_adult"
      },
      {
        "implications": {
          "CYP2B6": "Normal efavirenz metabolism"
        },
        "drugrecommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
        "classification": "Strong",
        "phenotypes": {
          "CYP2B6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Normal Metabolizer"
        },
        "comments": "The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype (PMID 24522178).",
        "population": "child >40kg_adult"
      },
      {
        "implications": {
          "CYP2B6": "Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation"
        },
        "drugrecommendation": "Consider initiating efavirenz with decreased dose of 400 or 200 mg/day",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2B6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Poor Metabolizer"
        },
        "comments": "If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.",
        "population": "child >40kg_adult"
      },
      {
        "implications": {
          "CYP2B6": "Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
        "classification": "Strong",
        "phenotypes": {
          "CYP2B6": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Rapid Metabolizer"
        },
        "comments": "n/a",
        "population": "child >40kg_adult"
      },
      {
        "implications": {
          "CYP2B6": "Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
        "classification": "Strong",
        "phenotypes": {
          "CYP2B6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2B6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2B6": "Ultrarapid Metabolizer"
        },
        "comments": "n/a",
        "population": "child >40kg_adult"
      }
    ]
  },
  {
    "drugid": "RxNorm:3920",
    "drugname": "enflurane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:321988",
    "drugname": "escitalopram",
    "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
    "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166127636",
      "PA166127637",
      "PA166127638",
      "PA166127639"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 110006,
        "guidelineid": 100413,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
        "authors": [
          "Hicks J Kevin",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Müller Daniel J",
          "Ji Yuan",
          "Leckband Susan G",
          "Leeder J Steven",
          "Graham Rebecca L",
          "Chiulli Dana L",
          "LLerena Adrián",
          "Skaar Todd C",
          "Scott Stuart A",
          "Stingl Julia C",
          "Klein Teri E",
          "Caudle Kelly E",
          "Gaedigk Andrea"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25974703",
        "pmcid": "PMC4512908",
        "doi": "10.1002/cpt.147",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:4492",
    "drugname": "fluorouracil",
    "guidelinename": "DPYD and Fluoropyrimidines",
    "url": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/",
    "guidelinepharmgkbids": [
      "PA166109594",
      "PA166122686",
      "PA166122687"
    ],
    "genes": [
      "DPYD"
    ],
    "citations": [
      {
        "id": 110019,
        "guidelineid": 100419,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing",
        "authors": [
          "Caudle Kelly E",
          "Thorn Caroline F",
          "Klein Teri E",
          "Swen Jesse J",
          "McLeod Howard L",
          "Diasio Robert B",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23988873",
        "pmcid": "PMC3831181",
        "doi": "10.1038/clpt.2013.172",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2013/23988873.pdf"
      },
      {
        "id": 110029,
        "guidelineid": 100419,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",
        "authors": [
          "Amstutz Ursula",
          "Henricks Linda M",
          "Offer Steven M",
          "Barbarino Julia",
          "Schellens Jan H M",
          "Swen Jesse J",
          "Klein Teri E",
          "McLeod Howard L",
          "Caudle Kelly E",
          "Diasio Robert B",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2017,
        "pmid": "29152729",
        "pmcid": "PMC5760397",
        "doi": "10.1002/cpt.911",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."
        },
        "drugrecommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Poor Metabolizer"
        },
        "activityscore": {
          "DPYD": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs."
        },
        "drugrecommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Poor Metabolizer"
        },
        "activityscore": {
          "DPYD": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "0.5"
        },
        "comments": "If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance. Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue therapy if the drug level is too high.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"
        },
        "drugrecommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Intermediate Metabolizer"
        },
        "activityscore": {
          "DPYD": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "1"
        },
        "comments": "Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs"
        },
        "drugrecommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
        "classification": "Moderate",
        "phenotypes": {
          "DPYD": "Intermediate Metabolizer"
        },
        "activityscore": {
          "DPYD": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "1.5"
        },
        "comments": "Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.",
        "population": "general"
      },
      {
        "implications": {
          "DPYD": "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity"
        },
        "drugrecommendation": "Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",
        "classification": "Strong",
        "phenotypes": {
          "DPYD": "Normal Metabolizer"
        },
        "activityscore": {
          "DPYD": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "DPYD": "2"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:4502",
    "drugname": "flurbiprofen",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:42355",
    "drugname": "fluvoxamine",
    "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
    "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166127636",
      "PA166127637",
      "PA166127638",
      "PA166127639"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110006,
        "guidelineid": 100413,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
        "authors": [
          "Hicks J Kevin",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Müller Daniel J",
          "Ji Yuan",
          "Leckband Susan G",
          "Leeder J Steven",
          "Graham Rebecca L",
          "Chiulli Dana L",
          "LLerena Adrián",
          "Skaar Todd C",
          "Scott Stuart A",
          "Stingl Julia C",
          "Klein Teri E",
          "Caudle Kelly E",
          "Gaedigk Andrea"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25974703",
        "pmcid": "PMC4512908",
        "doi": "10.1002/cpt.147",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine (PMID 22565785). However, a 30% decrease in dose may not be feasible given the dosage forms; therefore, decreasing the starting dose of fluvoxamine by 25-50% should be considered.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "No data available for CYP2D6 ultrarapid metabolizers"
        },
        "drugrecommendation": "No recommendation due to lack of evidence",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:72236",
    "drugname": "fosphenytoin",
    "guidelinename": "CYP2C9, HLA-B and Phenytoin",
    "url": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166122806"
    ],
    "genes": [
      "CYP2C9",
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110003,
        "guidelineid": 100412,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing",
        "authors": [
          "Caudle Kelly E",
          "Rettie Allan E",
          "Whirl-Carrillo Michelle",
          "Smith Lisa H",
          "Mintzer Scott E",
          "Lee Ming Ta Michael",
          "Klein Teri E",
          "Callaghan J Thomas"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "25099164",
        "pmcid": "PMC4206662",
        "doi": "10.1038/clpt.2014.159",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/phenytoin/2014/25099164.pdf"
      },
      {
        "id": 110077,
        "guidelineid": 100412,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.",
        "authors": [
          "Karnes Jason H",
          "Rettie Allan E",
          "Somogyi Andrew A",
          "Huddart Rachel",
          "Fohner Alison E",
          "Formea Christine M",
          "Lee Ming Ta Michael",
          "Llerena Adrian",
          "Whirl-Carrillo Michelle",
          "Klein Teri E",
          "Phillips Elizabeth J",
          "Mintzer Scott",
          "Gaedigk Andrea",
          "Caudle Kelly E",
          "Callaghan John T"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2020,
        "pmid": "32779747",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/phenytoin/2020/32779747.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0.5"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0.5"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1.5"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1.5"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "n/a",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "n/a",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0.5"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0.5"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1.5"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1.5"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "2"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "2"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "n/a"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "n/a"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      }
    ]
  },
  {
    "drugid": "RxNorm:5095",
    "drugname": "halothane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:5489",
    "drugname": "hydrocodone",
    "guidelinename": "CYP2D6, OPRM1, COMT, and Opioids",
    "url": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
    "guidelinepharmgkbids": [
      "PA166104996"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110031,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype",
        "authors": [
          "Crews K R",
          "Gaedigk A",
          "Dunnenberger H M",
          "Klein T E",
          "Shen D D",
          "Callaghan J T",
          "Kharasch E D",
          "Skaar T C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2011,
        "pmid": "22205192",
        "pmcid": "PMC3289963",
        "doi": "10.1038/clpt.2011.287",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192.pdf"
      },
      {
        "id": 110033,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update",
        "authors": [
          "Crews Kristine R",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steve",
          "Klein Teri E",
          "Caudle Kelly E",
          "Haidar Cyrine E",
          "Shen Danny D",
          "Callaghan John T",
          "Sadhasivam Senthilkumar",
          "Prows Cynthia A",
          "Kharasch Evan D",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24458010",
        "pmcid": "PMC3975212",
        "doi": "10.1038/clpt.2013.254",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010.pdf"
      },
      {
        "id": 417705,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.",
        "authors": [
          "Crews Kristine R",
          "Monte Andrew A",
          "Huddart Rachel",
          "Caudle Kelly E",
          "Kharasch Evan D",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steven",
          "Callaghan John T",
          "Samer Caroline Flora",
          "Klein Teri E",
          "Haidar Cyrine E",
          "Van Driest Sara L",
          "Ruano Gualberto",
          "Sangkuhl Katrin",
          "Cavallari Larisa H",
          "Müller Daniel J",
          "Prows Cynthia A",
          "Nagy Mohamed",
          "Somogyi Andrew A",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": null,
        "volume": null,
        "year": 2021,
        "pmid": "33387367",
        "pmcid": null,
        "doi": "10.1002/cpt.2149",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Decreased metabolism of hydrocodone to active metabolite, hydromorphone, but there is insufficient evidence to determine if these effects on pharmacokinetics translate into decreased analgesia or side effects."
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal hydromorphone formation"
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal hydromorphone formation"
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal hydromorphone formation"
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal hydromorphone formation"
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal hydromorphone formation"
        },
        "drugrecommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Minimal evidence for pharmacokinetic or clinical effect."
        },
        "drugrecommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:5640",
    "drugname": "ibuprofen",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:5691",
    "drugname": "imipramine",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2C19",
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:6026",
    "drugname": "isoflurane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:1243041",
    "drugname": "ivacaftor",
    "guidelinename": "CFTR and Ivacaftor",
    "url": "https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/",
    "guidelinepharmgkbids": [
      "PA166114461"
    ],
    "genes": [
      "CFTR"
    ],
    "citations": [
      {
        "id": 110023,
        "guidelineid": 100409,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype",
        "authors": [
          "Clancy John P",
          "Johnson Samuel G",
          "Yee Sook Wah",
          "McDonagh Ellen M",
          "Caudle Kelly E",
          "Klein Teri E",
          "Cannavo Matthew",
          "Giacomini Kathleen M"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24598717",
        "pmcid": "PMC4026598",
        "doi": "10.1038/clpt.2014.54",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/ivacaftor/2014/24598717.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CFTR": "An individual diagnosed with cystic fibrosis (CF) and negative for a CFTR variant listed in the FDA-approved drug label as being responsive to ivacaftor."
        },
        "drugrecommendation": "Ivacaftor is not recommended",
        "classification": "Moderate",
        "phenotypes": {
          "CFTR": "ivacaftor non-responsive in CF patients"
        },
        "activityscore": {
          "CFTR": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CFTR": "ivacaftor non-responsive in CF patients"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CFTR": "An individual diagnosed with cystic fibrosis (CF) and CFTR variants listed in the FDA-approved drug label as being responsive to ivacaftor"
        },
        "drugrecommendation": "Use ivacaftor according to the product label",
        "classification": "Moderate",
        "phenotypes": {
          "CFTR": "ivacaftor responsive in CF patients"
        },
        "activityscore": {
          "CFTR": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CFTR": "ivacaftor responsive in CF patients"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:17128",
    "drugname": "lansoprazole",
    "guidelinename": "CYP2C19 and Proton Pump Inhibitors",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166219103",
      "PA166219301"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 571447,
        "guidelineid": 110076,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
        "authors": [
          "Lima John J",
          "Thomas Cameron D",
          "Barbarino Julia",
          "Desta Zeruesenay",
          "Van Driest Sara L",
          "El Rouby Nihal",
          "Johnson Julie A",
          "Cavallari Larisa H",
          "Shakhnovich Valentina",
          "Thacker David L",
          "Scott Stuart A",
          "Schwab Matthias",
          "Uppugunduri Chakradhara Rao S",
          "Formea Christine M",
          "Franciosi James P",
          "Sangkuhl Katrin",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Gammal Roseann S",
          "Furuta Takahisa"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32770672",
        "pmcid": null,
        "doi": "10.1002/cpt.2015",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:20890",
    "drugname": "lornoxicam",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:41493",
    "drugname": "meloxicam",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:103",
    "drugname": "mercaptopurine",
    "guidelinename": "TPMT, NUDT15 and Thiopurines",
    "url": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/",
    "guidelinepharmgkbids": [
      "PA166104933",
      "PA166104945",
      "PA166104965"
    ],
    "genes": [
      "NUDT15",
      "TPMT"
    ],
    "citations": [
      {
        "id": 110017,
        "guidelineid": 100428,
        "title": "Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": "387-91",
        "volume": "89",
        "year": 2011,
        "pmid": "21270794",
        "pmcid": "PMC3098761",
        "doi": "10.1038/clpt.2010.320",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794.pdf"
      },
      {
        "id": 110024,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Hicks J K",
          "Schwab M",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23422873",
        "pmcid": "PMC3604643",
        "doi": "10.1038/clpt.2013.4",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873.pdf"
      },
      {
        "id": 110026,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.",
        "authors": [
          "Relling Mary V",
          "Schwab Matthias",
          "Whirl-Carrillo Michelle",
          "Suarez-Kurtz Guilherme",
          "Pui Ching-Hon",
          "Stein Charles M",
          "Moyer Ann M",
          "Evans William E",
          "Klein Teri E",
          "Antillon-Klussmann Federico Guillermo",
          "Caudle Kelly E",
          "Kato Motohiro",
          "Yeoh Allen E J",
          "Schmiegelow Kjeld",
          "Yang Jun J"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30447069",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, higher MeTIMP, this is the ‘normal’ pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no MeTIMP metabolites. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; low concentrations of MeTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:6857",
    "drugname": "methoxyflurane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:7531",
    "drugname": "nortriptyline",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of tricyclic antidepressants"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of tricyclic antidepressants"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of tricyclic antidepressants"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of tricyclic antidepressants"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of tricyclic antidepressants"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "Because CYP2D6 phenotype could not be assigned based on genotyping performed, therapuetic monitoring should be considered. If therapuetic monitoring cannot be performed, monitor closely for toxicity and/or efficacy.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:7646",
    "drugname": "omeprazole",
    "guidelinename": "CYP2C19 and Proton Pump Inhibitors",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166219103",
      "PA166219301"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 571447,
        "guidelineid": 110076,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
        "authors": [
          "Lima John J",
          "Thomas Cameron D",
          "Barbarino Julia",
          "Desta Zeruesenay",
          "Van Driest Sara L",
          "El Rouby Nihal",
          "Johnson Julie A",
          "Cavallari Larisa H",
          "Shakhnovich Valentina",
          "Thacker David L",
          "Scott Stuart A",
          "Schwab Matthias",
          "Uppugunduri Chakradhara Rao S",
          "Formea Christine M",
          "Franciosi James P",
          "Sangkuhl Katrin",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Gammal Roseann S",
          "Furuta Takahisa"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32770672",
        "pmcid": null,
        "doi": "10.1002/cpt.2015",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:26225",
    "drugname": "ondansetron",
    "guidelinename": "CYP2D6 and Ondansetron and Tropisetron",
    "url": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/",
    "guidelinepharmgkbids": [
      "PA166161954",
      "PA166161955"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110013,
        "guidelineid": 100417,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron",
        "authors": [
          "Bell Gillian C",
          "Caudle Kelly E",
          "Whirl-Carrillo Michelle",
          "Gordon Ronald J",
          "Hikino Keiko",
          "Prows Cynthia A",
          "Gaedigk Andrea",
          "Agundez Jose A G",
          "Sadhasivam Senthilkumar",
          "Klein Teri E",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "28002639",
        "pmcid": "PMC5479760",
        "doi": "10.1002/cpt.598",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/ondansetron/2016/28002639.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 poor metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:32624",
    "drugname": "oxcarbazepine",
    "guidelinename": "HLA-A, HLA-B and Carbamazepine and Oxcarbazepine",
    "url": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166105008",
      "PA166176623"
    ],
    "genes": [
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110009,
        "guidelineid": 100423,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing",
        "authors": [
          "Leckband Susan G",
          "Kelsoe John R",
          "Dunnenberger H Mark",
          "George Alfred L",
          "Tran Eric",
          "Berger Reisel",
          "Müller Daniel J",
          "Whirl-Carrillo Michelle",
          "Caudle Kelly E",
          "Pirmohamed Munir"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23695185",
        "pmcid": "PMC3748365",
        "doi": "10.1038/clpt.2013.103",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2013/23695185.pdf"
      },
      {
        "id": 110034,
        "guidelineid": 100423,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.",
        "authors": [
          "Phillips Elizabeth J",
          "Sukasem Chonlaphat",
          "Whirl-Carrillo Michelle",
          "Müller Daniel J",
          "Dunnenberger Henry M",
          "Chantratita Wasun",
          "Goldspiel Barry",
          "Chen Yuan-Tsong",
          "Carleton Bruce C",
          "George Alfred L",
          "Mushiroda Taisei",
          "Klein Teri",
          "Gammal Roseann S",
          "Pirmohamed Munir"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 4,
        "page": "574-581",
        "volume": "103",
        "year": 2018,
        "pmid": "29392710",
        "pmcid": "PMC5847474",
        "doi": "10.1002/cpt.1004",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/29392710.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative"
        },
        "comments": "n/a",
        "population": "OXC naive"
      },
      {
        "implications": {
          "HLA-B": "Normal risk of oxcarbazepine-induced SJS/TEN"
        },
        "drugrecommendation": "Use oxcarbazepine per standard dosing guidelines.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {
          "HLA-B": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative"
        },
        "comments": "n/a",
        "population": "OXC use >3 mos"
      },
      {
        "implications": {
          "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
        },
        "drugrecommendation": "If patient is oxcarbazepine-naïve, do not use oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {},
        "activityscore": {},
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive"
        },
        "comments": "Other aromatic anticonvulsants have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "population": "OXC naive"
      },
      {
        "implications": {
          "HLA-B": "Greater risk of oxcarbazepine-induced SJS/TEN"
        },
        "drugrecommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",
        "classification": "Optional",
        "phenotypes": {},
        "activityscore": {
          "HLA-B": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive"
        },
        "comments": "Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants. Aromatic anticonvulsants include carbamazepine, oxcarbazepine, eslicarbazepine, lamotrigine, phenytoin, fosphenytoin, and phenobarbital.",
        "population": "OXC use >3 mos"
      }
    ]
  },
  {
    "drugid": "RxNorm:40790",
    "drugname": "pantoprazole",
    "guidelinename": "CYP2C19 and Proton Pump Inhibitors",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166219103",
      "PA166219301"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 571447,
        "guidelineid": 110076,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
        "authors": [
          "Lima John J",
          "Thomas Cameron D",
          "Barbarino Julia",
          "Desta Zeruesenay",
          "Van Driest Sara L",
          "El Rouby Nihal",
          "Johnson Julie A",
          "Cavallari Larisa H",
          "Shakhnovich Valentina",
          "Thacker David L",
          "Scott Stuart A",
          "Schwab Matthias",
          "Uppugunduri Chakradhara Rao S",
          "Formea Christine M",
          "Franciosi James P",
          "Sangkuhl Katrin",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Gammal Roseann S",
          "Furuta Takahisa"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32770672",
        "pmcid": null,
        "doi": "10.1002/cpt.2015",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "The strength of recommendation for \"likely\" phenotypes are the same as their respective confirmed phenotypes. \"Likely\" indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding \"likely\" phenotype.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
        },
        "drugrecommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
        },
        "drugrecommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:32937",
    "drugname": "paroxetine",
    "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
    "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166127636",
      "PA166127637",
      "PA166127638",
      "PA166127639"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110006,
        "guidelineid": 100413,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
        "authors": [
          "Hicks J Kevin",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Müller Daniel J",
          "Ji Yuan",
          "Leckband Susan G",
          "Leeder J Steven",
          "Graham Rebecca L",
          "Chiulli Dana L",
          "LLerena Adrián",
          "Skaar Todd C",
          "Scott Stuart A",
          "Stingl Julia C",
          "Klein Teri E",
          "Caudle Kelly E",
          "Gaedigk Andrea"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25974703",
        "pmcid": "PMC4512908",
        "doi": "10.1002/cpt.147",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:120608",
    "drugname": "peginterferon alfa-2a",
    "guidelinename": "IFNL3 and Peginterferon-alpha-based Regimens",
    "url": "https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/",
    "guidelinepharmgkbids": [
      "PA166110235"
    ],
    "genes": [
      "IFNL3",
      "IFNL4"
    ],
    "citations": [
      {
        "id": 110007,
        "guidelineid": 100424,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens",
        "authors": [
          "Muir Andrew J",
          "Gong Li",
          "Johnson Samuel G",
          "Michael Lee Ming Ta",
          "Williams Marc S",
          "Klein Teri E",
          "Caudle Kelly E",
          "Nelson David R"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 10,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "24096968",
        "pmcid": "PMC3904555",
        "doi": "10.1038/clpt.2013.203",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/pegintron/2013/24096968.pdf"
      }
    ],
    "notesonusage": null
  },
  {
    "drugid": "RxNorm:253453",
    "drugname": "peginterferon alfa-2b",
    "guidelinename": "IFNL3 and Peginterferon-alpha-based Regimens",
    "url": "https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/",
    "guidelinepharmgkbids": [
      "PA166110235"
    ],
    "genes": [
      "IFNL3",
      "IFNL4"
    ],
    "citations": [
      {
        "id": 110007,
        "guidelineid": 100424,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens",
        "authors": [
          "Muir Andrew J",
          "Gong Li",
          "Johnson Samuel G",
          "Michael Lee Ming Ta",
          "Williams Marc S",
          "Klein Teri E",
          "Caudle Kelly E",
          "Nelson David R"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 10,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "24096968",
        "pmcid": "PMC3904555",
        "doi": "10.1038/clpt.2013.203",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/pegintron/2013/24096968.pdf"
      }
    ],
    "notesonusage": null
  },
  {
    "drugid": "RxNorm:8183",
    "drugname": "phenytoin",
    "guidelinename": "CYP2C9, HLA-B and Phenytoin",
    "url": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/",
    "guidelinepharmgkbids": [
      "PA166122806"
    ],
    "genes": [
      "CYP2C9",
      "HLA-B"
    ],
    "citations": [
      {
        "id": 110003,
        "guidelineid": 100412,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing",
        "authors": [
          "Caudle Kelly E",
          "Rettie Allan E",
          "Whirl-Carrillo Michelle",
          "Smith Lisa H",
          "Mintzer Scott E",
          "Lee Ming Ta Michael",
          "Klein Teri E",
          "Callaghan J Thomas"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "25099164",
        "pmcid": "PMC4206662",
        "doi": "10.1038/clpt.2014.159",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/phenytoin/2014/25099164.pdf"
      },
      {
        "id": 110077,
        "guidelineid": 100412,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.",
        "authors": [
          "Karnes Jason H",
          "Rettie Allan E",
          "Somogyi Andrew A",
          "Huddart Rachel",
          "Fohner Alison E",
          "Formea Christine M",
          "Lee Ming Ta Michael",
          "Llerena Adrian",
          "Whirl-Carrillo Michelle",
          "Klein Teri E",
          "Phillips Elizabeth J",
          "Mintzer Scott",
          "Gaedigk Andrea",
          "Caudle Kelly E",
          "Callaghan John T"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 8,
        "page": "",
        "volume": "",
        "year": 2020,
        "pmid": "32779747",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/phenytoin/2020/32779747.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0.5"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "0.5"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1.5"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "1.5"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "n/a",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "n/a",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "n/a",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 negative"
        },
        "lookupkey": {
          "HLA-B": "*15:02 negative",
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0.5"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "0.5"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Reduced phenytoin metabolism; Higher plasma concentrations will increase probability of toxicities."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1.5"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects."
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "1.5"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "2"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "Normal phenytoin metabolism"
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "2"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "n/a"
        },
        "comments": "Other aromatic anticonvulsants, including eslicarbazepine, lamotrigine, and phenobarbital, have weaker evidence linking SJS/TEN with the HLA-B*15:02 allele; however, caution should still be used in choosing an alternative agent.",
        "population": "PHT naive"
      },
      {
        "implications": {
          "HLA-B": "Increased risk of phenytoin-induced SJS/TEN",
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {
          "HLA-B": "HLA-B*15:02 positive"
        },
        "lookupkey": {
          "HLA-B": "*15:02 positive",
          "CYP2C9": "n/a"
        },
        "comments": "Previous tolerance of phenytoin is not indicative of tolerance to other aromatic anticonvulsants.",
        "population": "PHT use >3mos"
      }
    ]
  },
  {
    "drugid": "RxNorm:8356",
    "drugname": "piroxicam",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:283821",
    "drugname": "rasburicase",
    "guidelinename": "G6PD and Rasburicase",
    "url": "https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/",
    "guidelinepharmgkbids": [
      "PA166119846"
    ],
    "genes": [
      "G6PD"
    ],
    "citations": [
      {
        "id": 110000,
        "guidelineid": 100420,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype",
        "authors": [
          "Relling Mary V",
          "McDonagh Ellen M",
          "Chang Tamara",
          "Caudle Kelly E",
          "McLeod Howard L",
          "Haidar Cyrine E",
          "Klein Teri",
          "Luzzatto Lucio"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24787449",
        "pmcid": "PMC4111801",
        "doi": "10.1038/clpt.2014.97",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/rasburicase/2014/24787449.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "G6PD": "At risk of acute hemolytic anemia"
        },
        "drugrecommendation": "Rasburicase is contraindicated; alternatives include allopurinol.",
        "classification": "Strong",
        "phenotypes": {
          "G6PD": "Deficient"
        },
        "activityscore": {
          "G6PD": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "G6PD": "Deficient"
        },
        "comments": "Allopurinol is associated with severe cutaneous reactions in the rare carriers of the HLA-B*58:01 allele.",
        "population": "general"
      },
      {
        "implications": {
          "G6PD": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "G6PD": "Indeterminate"
        },
        "activityscore": {
          "G6PD": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "G6PD": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "G6PD": "Low or reduced risk of hemolytic anemia"
        },
        "drugrecommendation": "No reason to withhold rasburicase based on G6PD status.",
        "classification": "Strong",
        "phenotypes": {
          "G6PD": "Normal"
        },
        "activityscore": {
          "G6PD": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "G6PD": "Normal"
        },
        "comments": "A negative or inconclusive genetic test cannot be assumed to indicate normal G6PD phenotype; an enzyme actiity test is needed to assign G6PD phenotype in such cases.",
        "population": "general"
      },
      {
        "implications": {
          "G6PD": "Unknown risk of hemolytic anemia"
        },
        "drugrecommendation": "To ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol.",
        "classification": "Moderate",
        "phenotypes": {
          "G6PD": "Variable"
        },
        "activityscore": {
          "G6PD": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "G6PD": "Variable"
        },
        "comments": "Allopurinol is associated with severe cutaneous reactions in the rare carriers of the HLA-B*58:01 allele.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:36437",
    "drugname": "sertraline",
    "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
    "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166127636",
      "PA166127637",
      "PA166127638",
      "PA166127639"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 110006,
        "guidelineid": 100413,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
        "authors": [
          "Hicks J Kevin",
          "Bishop Jeffrey R",
          "Sangkuhl Katrin",
          "Müller Daniel J",
          "Ji Yuan",
          "Leckband Susan G",
          "Leeder J Steven",
          "Graham Rebecca L",
          "Chiulli Dana L",
          "LLerena Adrián",
          "Skaar Todd C",
          "Scott Stuart A",
          "Stingl Julia C",
          "Klein Teri E",
          "Caudle Kelly E",
          "Gaedigk Andrea"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25974703",
        "pmcid": "PMC4512908",
        "doi": "10.1002/cpt.147",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Reduced metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
        },
        "drugrecommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy. Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. (PMID 22565785).",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C19": "Increased metabolism when compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:36453",
    "drugname": "sevoflurane",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:36567",
    "drugname": "simvastatin",
    "guidelinename": "SLCO1B1 and Simvastatin",
    "url": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/",
    "guidelinepharmgkbids": [
      "PA166105005"
    ],
    "genes": [
      "SLCO1B1"
    ],
    "citations": [
      {
        "id": 110021,
        "guidelineid": 100426,
        "title": "The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy",
        "authors": [
          "Wilke R A",
          "Ramsey L B",
          "Johnson S G",
          "Maxwell W D",
          "McLeod H L",
          "Voora D",
          "Krauss R M",
          "Roden D M",
          "Feng Q",
          "Cooper-Dehoff R M",
          "Gong L",
          "Klein T E",
          "Wadelius M",
          "Niemi M"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2012,
        "pmid": "22617227",
        "pmcid": "PMC3384438",
        "doi": "10.1038/clpt.2012.57",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/simvastatin/2012/22617227.pdf"
      },
      {
        "id": 110022,
        "guidelineid": 100426,
        "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update",
        "authors": [
          "Ramsey Laura B",
          "Johnson Samuel G",
          "Caudle Kelly E",
          "Haidar Cyrine E",
          "Voora Deepak",
          "Wilke Russell A",
          "Maxwell Whitney D",
          "McLeod Howard L",
          "Krauss Ronald M",
          "Roden Dan M",
          "Feng Qiping",
          "Cooper-DeHoff Rhonda M",
          "Gong Li",
          "Klein Teri E",
          "Wadelius Mia",
          "Niemi Mikko"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 6,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24918167",
        "pmcid": "PMC4169720",
        "doi": "10.1038/clpt.2014.125",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/simvastatin/2014/24918167.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "SLCO1B1": "Intermediate myopathy risk"
        },
        "drugrecommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
        "classification": "Strong",
        "phenotypes": {
          "SLCO1B1": "Decreased Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Decreased Function"
        },
        "comments": "In all cases, the potential for drug-drug interactions should be evaluated prior to initiating a prescription.",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "SLCO1B1": "Indeterminate"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "Normal myopathy risk"
        },
        "drugrecommendation": "Prescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines",
        "classification": "Strong",
        "phenotypes": {
          "SLCO1B1": "Normal Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Normal Function"
        },
        "comments": "In all cases, the potential for drug-drug interactions should be evaluated before initiating a prescription. The US Food and Drug Administration recommends against 80 mg (unless already tolerated for 12 months).",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "High myopathy risk"
        },
        "drugrecommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
        "classification": "Strong",
        "phenotypes": {
          "SLCO1B1": "Poor Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Poor Function"
        },
        "comments": "In all cases, the potential for drug-drug interactions should be evaluated prior to initiating a prescription.",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "Intermediate myopathy risk"
        },
        "drugrecommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
        "classification": "Strong",
        "phenotypes": {
          "SLCO1B1": "Possible Decreased Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Possible Decreased Function"
        },
        "comments": "In all cases, the potential for drug-drug interactions should be evaluated prior to initiating a prescription.",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "SLCO1B1": "Possible Increased Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Possible Increased Function"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "SLCO1B1": "High myopathy risk"
        },
        "drugrecommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
        "classification": "Strong",
        "phenotypes": {
          "SLCO1B1": "Possible Poor Function"
        },
        "activityscore": {
          "SLCO1B1": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "SLCO1B1": "Possible Poor Function"
        },
        "comments": "In all cases, the potential for drug-drug interactions should be evaluated prior to initiating a prescription.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:10154",
    "drugname": "succinylcholine",
    "guidelinename": "RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/",
    "guidelinepharmgkbids": [
      "PA166180457"
    ],
    "genes": [
      "CACNA1S",
      "RYR1"
    ],
    "citations": [
      {
        "id": 110032,
        "guidelineid": 100427,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes",
        "authors": [
          "Gonsalves Stephen G",
          "Dirksen Robert T",
          "Sangkuhl Katrin",
          "Pulk Rebecca",
          "Alvarellos Maria",
          "Vo Teresa",
          "Hikino Keiko",
          "Roden Dan",
          "Klein Teri",
          "Mark Poler S",
          "Patel Sephalie",
          "Caudle Kelly E",
          "Gordon Ronald",
          "Brandom Barbara",
          "Biesecker Leslie G"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30499100",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "RYR1": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Malignant Hyperthermia Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine"
        },
        "drugrecommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Malignant Hyperthermia Susceptibility"
        },
        "comments": "A list of unsafe halogenated volatile anesthetics or depolarizing muscle relaxants and alternative anesthetics can be found at http://www.mhaus.org/healthcare-professionals/be-prepared/safe-and-unsafe-anesthetics. Individuals who have biallelic (homozygous or compound heterozygous) pathogenic variants in RYR1 generally will have autosomal recessive myopathies and should be managed according to the standard of care for those disorders. Although some may, indeed, have susceptibility to anesthetic agents, the recommendations described here cannot adequately address such patients, and they should be managed by a physician who is knowledgeable regarding those disorders.",
        "population": "general"
      },
      {
        "implications": {
          "RYR1": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675).",
          "CACNA1S": "These results do not eliminate the chance that this patient is susceptible to malignant hyperthermia (MH). The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown (PMID 28902675)."
        },
        "drugrecommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
        "classification": "Strong",
        "phenotypes": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "activityscore": {
          "RYR1": "n/a",
          "CACNA1S": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "RYR1": "Uncertain Susceptibility",
          "CACNA1S": "Uncertain Susceptibility"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:42316",
    "drugname": "tacrolimus",
    "guidelinename": "CYP3A5 and Tacrolimus",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/",
    "guidelinepharmgkbids": [
      "PA166124619"
    ],
    "genes": [
      "CYP3A5"
    ],
    "citations": [
      {
        "id": 110002,
        "guidelineid": 100418,
        "title": "Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing",
        "authors": [
          "Birdwell Kelly A",
          "Decker Brian",
          "Barbarino Julia M",
          "Peterson Josh F",
          "Stein C Michael",
          "Sadee Wolfgang",
          "Wang Danxin",
          "Vinks Alexander A",
          "He Yijing",
          "Swen Jesse J",
          "Leeder J Steven",
          "van Schaik R H N",
          "Thummel Kenneth E",
          "Klein Teri E",
          "Caudle Kelly E",
          "MacPhee Iain A M"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": "",
        "volume": "",
        "year": 2015,
        "pmid": "25801146",
        "pmcid": "PMC4481158",
        "doi": "10.1002/cpt.113",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/tacrolimus/2015/25801146.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP3A5": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP3A5": "Indeterminate"
        },
        "activityscore": {
          "CYP3A5": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP3A5": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP3A5": "Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
        },
        "drugrecommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP3A5": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP3A5": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP3A5": "Intermediate Metabolizer"
        },
        "comments": "This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP3A5": "Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
        },
        "drugrecommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP3A5": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP3A5": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP3A5": "Normal Metabolizer"
        },
        "comments": "This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP3A5": "Higher (\"normal\") dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations."
        },
        "drugrecommendation": "Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP3A5": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP3A5": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP3A5": "Poor Metabolizer"
        },
        "comments": "This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP3A5": "Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
        },
        "drugrecommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Strong",
        "phenotypes": {
          "CYP3A5": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP3A5": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP3A5": "Possible Intermediate Metabolizer"
        },
        "comments": "This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:10324",
    "drugname": "tamoxifen",
    "guidelinename": "CYP2D6 and Tamoxifen",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/",
    "guidelinepharmgkbids": [
      "PA166176068"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110010,
        "guidelineid": 100415,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.",
        "authors": [
          "Goetz Matthew P",
          "Sangkuhl Katrin",
          "Guchelaar Henk-Jan",
          "Schwab Matthias",
          "Province Michael",
          "Whirl-Carrillo Michelle",
          "Symmans W Fraser",
          "McLeod Howard L",
          "Ratain Mark J",
          "Zembutsu Hitoshi",
          "Gaedigk Andrea",
          "van Schaik Ron H",
          "Ingle James N",
          "Caudle Kelly E",
          "Klein Teri E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 5,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "29385237",
        "pmcid": "PMC5931215",
        "doi": "10.1002/cpt.1007",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/tamoxifen/2017/29385237.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
        },
        "drugrecommendation": "Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
        },
        "drugrecommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
        },
        "drugrecommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
        },
        "drugrecommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
        },
        "drugrecommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Therapeutic endoxifen concentrations"
        },
        "drugrecommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:37790",
    "drugname": "tenoxicam",
    "guidelinename": "CYP2C9 and NSAIDs",
    "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
    "guidelinepharmgkbids": [
      "PA166191841"
    ],
    "genes": [
      "CYP2C9"
    ],
    "citations": [
      {
        "id": 571448,
        "guidelineid": 110058,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
        "authors": [
          "Theken Katherine N",
          "Lee Craig R",
          "Gong Li",
          "Caudle Kelly E",
          "Formea Christine M",
          "Gaedigk Andrea",
          "Klein Teri E",
          "Agúndez José A G",
          "Grosser Tilo"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": null,
        "volume": null,
        "year": 2020,
        "pmid": "32189324",
        "pmcid": null,
        "doi": "10.1002/cpt.1830",
        "url": null,
        "version": 4,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "0.5"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
        },
        "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
        "classification": "Optional",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1"
        },
        "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Mildly reduced metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C9": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "1.5"
        },
        "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C9": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2C9": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2C9": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C9": "Indeterminate"
        },
        "activityscore": {
          "CYP2C9": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2C9": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:10485",
    "drugname": "thioguanine",
    "guidelinename": "TPMT, NUDT15 and Thiopurines",
    "url": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/",
    "guidelinepharmgkbids": [
      "PA166104933",
      "PA166104945",
      "PA166104965"
    ],
    "genes": [
      "NUDT15",
      "TPMT"
    ],
    "citations": [
      {
        "id": 110017,
        "guidelineid": 100428,
        "title": "Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 3,
        "page": "387-91",
        "volume": "89",
        "year": 2011,
        "pmid": "21270794",
        "pmcid": "PMC3098761",
        "doi": "10.1038/clpt.2010.320",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794.pdf"
      },
      {
        "id": 110024,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update",
        "authors": [
          "Relling M V",
          "Gardner E E",
          "Sandborn W J",
          "Schmiegelow K",
          "Pui C-H",
          "Yee S W",
          "Stein C M",
          "Carrillo M",
          "Evans W E",
          "Hicks J K",
          "Schwab M",
          "Klein T E"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23422873",
        "pmcid": "PMC3604643",
        "doi": "10.1038/clpt.2013.4",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873.pdf"
      },
      {
        "id": 110026,
        "guidelineid": 100428,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update.",
        "authors": [
          "Relling Mary V",
          "Schwab Matthias",
          "Whirl-Carrillo Michelle",
          "Suarez-Kurtz Guilherme",
          "Pui Ching-Hon",
          "Stein Charles M",
          "Moyer Ann M",
          "Evans William E",
          "Klein Teri E",
          "Antillon-Klussmann Federico Guillermo",
          "Caudle Kelly E",
          "Kato Motohiro",
          "Yeoh Allen E J",
          "Schmiegelow Kjeld",
          "Yang Jun J"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 11,
        "page": "",
        "volume": "",
        "year": 2018,
        "pmid": "30447069",
        "pmcid": null,
        "doi": null,
        "url": null,
        "version": 5,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "No Result"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Indeterminate",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Indeterminate"
        },
        "comments": "Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "n/a",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "No Result",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Normal Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Poor Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Indeterminate"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "n/a"
        },
        "drugrecommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "No Result"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Normal Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
        "classification": "Strong",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Poor Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.",
        "population": "general"
      },
      {
        "implications": {
          "TPMT": "Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression",
          "NUDT15": "Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression"
        },
        "drugrecommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
        "classification": "Moderate",
        "phenotypes": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "activityscore": {
          "TPMT": "n/a",
          "NUDT15": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "TPMT": "Possible Intermediate Metabolizer",
          "NUDT15": "Possible Intermediate Metabolizer"
        },
        "comments": "Normal starting doses vary by race/ethnicity and treatment regimens. If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers. For patients who are intermediate metabolizers for both TPMT and NUDT15, further dose reduction might be needed compared with those who are only intermediate metabolizers with respect to one gene (TPMT or NUDT15).",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:10689",
    "drugname": "tramadol",
    "guidelinename": "CYP2D6, OPRM1, COMT, and Opioids",
    "url": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/",
    "guidelinepharmgkbids": [
      "PA166104996"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110031,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype",
        "authors": [
          "Crews K R",
          "Gaedigk A",
          "Dunnenberger H M",
          "Klein T E",
          "Shen D D",
          "Callaghan J T",
          "Kharasch E D",
          "Skaar T C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2011,
        "pmid": "22205192",
        "pmcid": "PMC3289963",
        "doi": "10.1038/clpt.2011.287",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192.pdf"
      },
      {
        "id": 110033,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update",
        "authors": [
          "Crews Kristine R",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steve",
          "Klein Teri E",
          "Caudle Kelly E",
          "Haidar Cyrine E",
          "Shen Danny D",
          "Callaghan John T",
          "Sadhasivam Senthilkumar",
          "Prows Cynthia A",
          "Kharasch Evan D",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2014,
        "pmid": "24458010",
        "pmcid": "PMC3975212",
        "doi": "10.1038/clpt.2013.254",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010.pdf"
      },
      {
        "id": 417705,
        "guidelineid": 100416,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy.",
        "authors": [
          "Crews Kristine R",
          "Monte Andrew A",
          "Huddart Rachel",
          "Caudle Kelly E",
          "Kharasch Evan D",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Leeder J Steven",
          "Callaghan John T",
          "Samer Caroline Flora",
          "Klein Teri E",
          "Haidar Cyrine E",
          "Van Driest Sara L",
          "Ruano Gualberto",
          "Sangkuhl Katrin",
          "Cavallari Larisa H",
          "Müller Daniel J",
          "Prows Cynthia A",
          "Nagy Mohamed",
          "Somogyi Andrew A",
          "Skaar Todd C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": null,
        "volume": null,
        "year": 2021,
        "pmid": "33387367",
        "pmcid": null,
        "doi": "10.1002/cpt.2149",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced O-desmethyltramadol (active metabolite) formation leading to diminished analgesia."
        },
        "drugrecommendation": "Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Expected O-desmethyltramadol (active metabolite) formation"
        },
        "drugrecommendation": "Use tramadol label recommended age- or weight-specific dosing.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity"
        },
        "drugrecommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:10834",
    "drugname": "trimipramine",
    "guidelinename": "CYP2D6, CYP2C19 and Tricyclic Antidepressants",
    "url": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166104998",
      "PA166104999",
      "PA166105000",
      "PA166105001",
      "PA166105002",
      "PA166105006",
      "PA166105007"
    ],
    "genes": [
      "CYP2C19",
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110004,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update",
        "authors": [
          "Kevin Hicks J",
          "Sangkuhl Katrin",
          "Swen Jesse J",
          "Ellingrod Vicki L",
          "Müller Daniel J",
          "Shimoda Kazutaka",
          "Bishop Jeffrey R",
          "Kharasch Evan D",
          "Skaar Todd C",
          "Gaedigk Andrea",
          "Dunnenberger Henry M",
          "Klein Teri E",
          "Caudle Kelly E",
          "Stingl Julia C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27997040",
        "pmcid": "PMC5478479",
        "doi": "10.1002/cpt.597",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040.pdf"
      },
      {
        "id": 110011,
        "guidelineid": 100414,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants",
        "authors": [
          "Hicks J K",
          "Swen J J",
          "Thorn C F",
          "Sangkuhl K",
          "Kharasch E D",
          "Ellingrod V L",
          "Skaar T C",
          "Müller D J",
          "Gaedigk A",
          "Stingl J C"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 1,
        "page": "",
        "volume": "",
        "year": 2013,
        "pmid": "23486447",
        "pmcid": "PMC3689226",
        "doi": "10.1038/clpt.2013.2",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Indeterminate"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "No Result"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism of TCAs",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "No Result"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "No Result"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "Indeterminate",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Normal metabolism of tertiary amines"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a",
          "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"
        },
        "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
        "classification": "Optional",
        "phenotypes": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "No result",
          "CYP2C19": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "No Result",
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:27392",
    "drugname": "tropisetron",
    "guidelinename": "CYP2D6 and Ondansetron and Tropisetron",
    "url": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/",
    "guidelinepharmgkbids": [
      "PA166161954",
      "PA166161955"
    ],
    "genes": [
      "CYP2D6"
    ],
    "citations": [
      {
        "id": 110013,
        "guidelineid": 100417,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron",
        "authors": [
          "Bell Gillian C",
          "Caudle Kelly E",
          "Whirl-Carrillo Michelle",
          "Gordon Ronald J",
          "Hikino Keiko",
          "Prows Cynthia A",
          "Gaedigk Andrea",
          "Agundez Jose A G",
          "Sadhasivam Senthilkumar",
          "Klein Teri E",
          "Schwab Matthias"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "28002639",
        "pmcid": "PMC5479760",
        "doi": "10.1002/cpt.598",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/ondansetron/2016/28002639.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 poor metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Poor Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "0.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "0.75"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Very limited data available for CYP2D6 intermediate metabolizers"
        },
        "drugrecommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Intermediate Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "1.75"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "1.75"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Normal metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended starting dose.",
        "classification": "Strong",
        "phenotypes": {
          "CYP2D6": "Normal Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "2.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "2.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.25"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.25"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "3.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "3.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "4.0"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥4.5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥4.5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥5"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥5"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting)."
        },
        "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2D6": "Ultrarapid Metabolizer"
        },
        "activityscore": {
          "CYP2D6": "≥6"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "≥6"
        },
        "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy. Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6. Limited evidence is available regarding the utilization of CYP2D6 genetic variation to guide use of these drugs.",
        "population": "general"
      },
      {
        "implications": {
          "CYP2D6": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2D6": "Indeterminate"
        },
        "activityscore": {
          "CYP2D6": "n/a"
        },
        "allelestatus": {},
        "lookupkey": {
          "CYP2D6": "n/a"
        },
        "comments": "n/a",
        "population": "general"
      }
    ]
  },
  {
    "drugid": "RxNorm:121243",
    "drugname": "voriconazole",
    "guidelinename": "CYP2C19 and Voriconazole",
    "url": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/",
    "guidelinepharmgkbids": [
      "PA166161537"
    ],
    "genes": [
      "CYP2C19"
    ],
    "citations": [
      {
        "id": 110001,
        "guidelineid": 100410,
        "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy",
        "authors": [
          "Moriyama Brad",
          "Obeng Aniwaa Owusu",
          "Barbarino Julia",
          "Penzak Scott R",
          "Henning Stacey A",
          "Scott Stuart A",
          "Agúndez José A G",
          "Wingard John R",
          "McLeod Howard L",
          "Klein Teri E",
          "Cross Shane",
          "Caudle Kelly E",
          "Walsh Thomas J"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 12,
        "page": "",
        "volume": "",
        "year": 2016,
        "pmid": "27981572",
        "pmcid": "PMC5474211",
        "doi": "10.1002/cpt.583",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/voriconazole/2016/27981572.pdf"
      }
    ],
    "notesonusage": null,
    "recommendations": [
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "n/a"
        },
        "drugrecommendation": "No recommendation",
        "classification": "No Recommendation",
        "phenotypes": {
          "CYP2C19": "Indeterminate"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Indeterminate"
        },
        "comments": "n/a",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Intermediate Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole compared with normal metabolizers"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Intermediate Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Likely Poor Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Normal voriconazole metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "Normal voriconazole metabolism"
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing",
        "classification": "Strong",
        "phenotypes": {
          "CYP2C19": "Normal Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Normal Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendation based upon data extrapolated from adults.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Poor Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Poor Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "In patients for whom a rapid metabolizer genotype (*1/*17) is identified, the probability of attainment of therapeutic concentrations is variable."
        },
        "drugrecommendation": "Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Rapid Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring (TDM), and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible. Meticulous TDM is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.",
        "population": "pediatrics"
      },
      {
        "implications": {
          "CYP2C19": "In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype.",
        "population": "adults"
      },
      {
        "implications": {
          "CYP2C19": "In patients for whom an ultrarapid metabolizer genotype (*17/*17) is identified, the probability of attainment of therapeutic concentrations is small"
        },
        "drugrecommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.",
        "classification": "Moderate",
        "phenotypes": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "activityscore": {},
        "allelestatus": {},
        "lookupkey": {
          "CYP2C19": "Ultrarapid Metabolizer"
        },
        "comments": "Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, therapeutic drug monitoring, and comorbidities. Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.",
        "population": "pediatrics"
      }
    ]
  },
  {
    "drugid": "RxNorm:11289",
    "drugname": "warfarin",
    "guidelinename": "CYP2C9, VKORC1, CYP4F2 and Warfarin",
    "url": "https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/",
    "guidelinepharmgkbids": [
      "PA166104949"
    ],
    "genes": [
      "CYP2C9",
      "CYP4F2",
      "VKORC1"
    ],
    "citations": [
      {
        "id": 110016,
        "guidelineid": 100425,
        "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing",
        "authors": [
          "Johnson J A",
          "Gong L",
          "Whirl-Carrillo M",
          "Gage B F",
          "Scott S A",
          "Stein C M",
          "Anderson J L",
          "Kimmel S E",
          "Lee M T M",
          "Pirmohamed M",
          "Wadelius M",
          "Klein T E",
          "Altman R B"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 9,
        "page": "",
        "volume": "",
        "year": 2011,
        "pmid": "21900891",
        "pmcid": "PMC3187550",
        "doi": "10.1038/clpt.2011.185",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/21900891.pdf"
      },
      {
        "id": 110030,
        "guidelineid": 100425,
        "title": "Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update",
        "authors": [
          "Johnson Julie A",
          "Caudle Kelly E",
          "Gong Li",
          "Whirl-Carrillo Michelle",
          "Stein C Michael",
          "Scott Stuart A",
          "Lee Ming Ta Michael",
          "Gage Brian F",
          "Kimmel Stephen E",
          "Perera Minoli A",
          "Anderson Jeffrey L",
          "Pirmohamed Munir",
          "Klein Teri E",
          "Limdi Nita A",
          "Cavallari Larisa H",
          "Wadelius Mia"
        ],
        "journal": "Clinical pharmacology and therapeutics",
        "month": 2,
        "page": "",
        "volume": "",
        "year": 2017,
        "pmid": "28198005",
        "pmcid": "PMC5546947",
        "doi": "10.1002/cpt.668",
        "url": null,
        "version": 3,
        "highlightedonsite": false,
        "fulltextfile": "https://files.cpicpgx.org/data/guideline/publication/warfarin/2017/28198005.pdf"
      }
    ],
    "notesonusage": "Warfarin recommendation does not follow simple diplotype to phenotype translation. Read the guideline text and follow the recommendation diagram found at http://files.cpicpgx.org/images/warfarin/warfarin_recommendation_diagram.png"
  }
]